Current and completed investments

Sciety is specialised in growth companies within life science. We invest in biotechnology, digital health, ICT in healthcare, pharmaceuticals and medical technology.

Current investments

Receive information about upcoming investment opportunities

Sign up below to get information about upcoming investment opportunities and investor lunch meetings with the companies’ managements.

Completed investments

The Sciety syndicate invests in Synartro Synartro is developing a novel therapy for knee osteoarthritis.

Synartro

Osteoarthritis affects more than 240 million people globally. Synartro is developing a novel therapy for knee osteoarthritis with fewer side effects and improved efficacy to meet the needs of the ageing population.

Cavis Technologies

Cavis Technologies has developed a combined guidewire/catheter, Wirecath®, for diagnosis of people with coronary heart disease. Wirecath® is expected to provide important clinical benefits.

Sciety_invests_in_Elypta

Elypta

Elypta has developed a new method for early cancer diagnosis. Liquid Biopsy is a rapidly growing field that is expected to be of great importance for cancer diagnosis.

Athera Biotechnologies

The company is in Phase II with a pharmaceutical candidate for a life-threatening illness for which there are currently no sufficient therapies.

Exits

Inhalation Sciences

Inhalation Sciences’ technology is used by prominent players within the chemical and pharma sectors to study how airborne particles impact the human body.

Attana

With Attana’s patented technology, pharmaceutical companies can evaluate, in an early development stage, how drug candidates impact the body and can identify the risk of side effects.

Raytelligence

Raytelligence has developed a unique, non-intrusive radar sensor and cloud platform for monitoring vital signs, such as respiration, heartbeat and position and movement. The company is aimed at elderly care in the home.

Liv Diagnostics

Tumor cell proliferation causes 90% of all cancer deaths. Liv Diagnostics is developing new technology to measure the spreading capacity of tumor cells and provide predictive information on the risk of metastasis.